SBIR Phase II: An AI-Enhanced Angiographic System to Guide Endovascular Treatment of Intracranial Aneurysms

SBIR II 期：人工智能增强血管造影系统指导颅内动脉瘤的血管内治疗

• 批准号: 2304388
• 负责人: Mohammad Mahdi Shiraz Bhurwani
• 金额: $ 99.99万
• 依托单位: QAS.AI INC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2304388&HistoricalAwards=false
• 关键词: SBIR; Phase; II; AI; Enhanced

The broader impact of this Small Business Innovation Research (SBIR) Phase II project is improving the surgical outcome for patients undergoing neuro-endovascular interventions for the treatment of intracranial aneurysms (IAs). IAs affect 6% of the population and IA rupture results in lethal hemorrhagic strokes, which account for ~25% of cerebrovascular deaths despite improvements in management. Most ruptured IA patients (~65%) die due to the initial bleed or its immediate complications. Of the survivors, ~50% are left disabled and dependent on others for daily activities. When IAs become symptomatic and medical therapy or lifestyle changes are ineffective, treatment could involve neuro-endovascular interventions. Although these surgical approaches provide reliable and fast access to the lesion with fewer complications than open skull surgery, they do not achieve complete IA healing, with as many as 30% of the cases requiring repeated interventions. The artificial intelligence technology developed in this project will allow real-time assessment of the surgery progress by analyzing images acquired through the angiographic unit. The solution will provide the odds of failure to achieve healing of the IAs before the patient leaves the surgical suite.This Small Business Innovation Research (SBIR) Phase II project will support development of the world’s first artificial intelligence platform that enables real-time informed decision support for image-guided neuro interventions to treat intracranial aneurysms. The technology uses imaging biomarkers extracted from routinely acquired angiograms during image-guided endovascular procedures and machine learning methods to account for large heterogeneity in patient pathology, neuro-interventionalist approach, and imaging equipment characteristics. The platform includes multiple innovative aspects: 1) a fully automated method to identify the location and extent of the IA, (2) instantaneous extraction of the imaging biomarkers, (3) prognosis of the surgical outcome at one-year post-procedure in a fraction of a second to allow neuro-interventionalist to readjust the endovascular therapy, and (4) full integration with the angiographic systems regardless of the manufacturer.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的广泛影响正在改善接受神经内血管干预措施治疗颅内动脉瘤（IAS）的患者的手术结果。 IAS影响了6％的人口和IA破裂导致致命的出血性中风，占管理脑血管死亡人数占管理目的地改善的25％。大多数破裂的IA患者（约65％）因初次出血或其直接并发症而死亡。在生存中，约有50％的人被残疾，并取决于其他活动进行日常活动。当IAS成为有症状的医疗治疗或生活方式的改变是无效的时，治疗可能涉及神经内血管干预措施。尽管这些外科手术方法比开放式颅骨手术更少，可靠地进入病变的并发症，但它们并没有实现完全的IA愈合，多达30％的病例需要反复干预。该项目中开发的人工智能技术将通过分析通过血管造影单元获得的图像进行实时评估。该解决方案将在患者离开外科套件之前，提供无法实现IAS治愈的几率。这项小型企业创新研究（SBIR）II期项目将支持世界上第一个人工智能平台的开发，该平台为图像引导的神经干预措施提供实时知情的决策支持，以治疗颅内动脉瘤。该技术使用在图像引导的血管内手术和机器学习方法中从常规获得的血管造影中提取的成像生物标志物来说明患者病理学，神经间距性方法和成像设备特征的较大异质性。该平台包括多个创新方面：1）一种完全自动化的方法，可以识别IA的位置和程度，（2）瞬时提取成像生物标志物的瞬时提取，（3）在一年的后期进行手术结果的预后，以允许Neuro Inerostragention secont，以预测伙伴关系，以预先构建良好的系统，并完整地集成了内脏的疗法，（4）制造商。该奖项反映了NSF的法定任务，并通过使用基金会的知识分子优点和更广泛的影响审查标准进行评估，被认为值得支持。